Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)
Phase II Feasibility Study of Weekly Paclitaxel Plus Weekly Trastuzumab Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide Plus Weekly Trastuzumab for Locally Advanced HER2-Positive Breast Cancer
Sponsor: Fundação Faculdade de Medicina
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Fundação Faculdade de Medicina
- Breast Cancer · Phase PHASE2 · May 2018
- Locally Advanced HER2-negative Breast Cancer · Phase PHASE2 · Aug 2012
More terminations from Fundação Faculdade de Medicina
A PHASE2 clinical study on Locally Advanced HER2-positive Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Fundação Faculdade de Medicina and has accumulated 6 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundação Faculdade de Medicina
- Instituto do Cancer do Estado de São Paulo
For direct contact, visit the study record on ClinicalTrials.gov .